Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System

Overview

This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2. The data collected from this study will serve the purpose of confirming safety and performance of the Zimmer Stafit Acetabular System.

Full Title of Study: “Post Market Clinical Follow-Up Study of the Zimmer Stafit Acetabular System. A Multicenter, Prospective, Non-controlled Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 24, 2017

Detailed Description

The objective of this study is to obtain implant survival and outcome data on the Stafit Acetabular System by analysis of standard scoring systems, radiographs, and adverse event records. Data will be used to monitor pain, mobility, dislocation rate and implant survival, and to confirm the long-term safety and performance of the Stafit Acetabular System in primary total hip arthroplasty. The study design is a multi-center, prospective, non-controlled, consecutive cohort post market clinical follow-up study, involving orthopedic surgeons skilled in total hip arthroplasty procedures and experienced with the Stafit Acetabular System.

Interventions

  • Device: Patients who received the Stafit Acetabular System
    • Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.

Clinical Trial Outcome Measures

Primary Measures

  • Implant Survival
    • Time Frame: 3 years postoperatively, due to early study termination
    • Represents the implants that survived by counting the number of implants revised.
  • Dislocation Rate
    • Time Frame: 2 years
    • Assessed by counting the number of implant dislocations

Secondary Measures

  • Evaluation of Pain and Functional Performance Determined by the Harris Hip Score
    • Time Frame: 3 years postoperatively, due to early study termination
    • The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed for walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a minimum of 0 (worst possible score) to a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).
  • Confirmation of Safety Based on Complications
    • Time Frame: 3 years postoperatively, due to early study termination
    • Reported number of patients with adverse events related to the implant. Adverse events include: dislocations of the hip, revisions and removals of the implants

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females – Patients suffering from severe hip pain and disability requiring a primary total hip arthroplasty. – 18 years minimum – Patients able to participate in a follow-up program based upon physical examination and medical history – Patients who have provided written informed consent by signing the Patient Informed Consent Form. Exclusion Criteria:

  • Patients who are unwilling or unable to give informed consent, or to comply with the follow-up program – Known pregnancy – Revision hip arthroplasty

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Zimmer Biomet
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Paola Vivoda, Study Director, Zimmer Biomet

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.